700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Short Communication Open Access
Rosiglitazone is a second-generation aminopyridyl thiazolidinedione that has been observed to be a safe and effective oral glucose-lowering agent in diabetic patients. In the present study two different preparations containing 2 mg rosiglitazone were compared in twelve healthy Indian human male volunteers under fasting condition. The trial was performed in a randomized two-way crossover design with a wash out period of one week. Rosiglitazone was extracted from human plasma using liquid-liquid method of extraction. HPLC method was used to determine the plasma concentration of the drug.
To read the full article Peer-reviewed Article PDF
Author(s): Mary Francis A A Moghe S R Pawar S S Khedkar